NCT Number: NCT00277823
Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder
The purpose of this study is to compare the antidepressant efficacy, safety, and tolerability of DVS-SR in subjects receiving daily doses of 50 mg or 100 mg of DVS-SR versus subjects receiving placebo.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
Beverly Hills, California, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Clinical diagnosis of major depressive disorder
- Must be able to swallow tablets
- Must be at least 18 years of age.
Exclusion criteria
- Clinical diagnosis of other psychiatric disorders
- Significant risk of suicide
- Unstable medical conditions.
Treatment and study plan
DVS-SR 100 mg
DrugPlacebo
DrugPrimary outcomes
-
The primary objective is to compare the antidepressant efficacy, safety, and tolerability of DVS-SR in subjects receiving daily doses of 50 mg or 100 mg of DVS SR versus subjects receiving placebo.
Secondary outcomes
-
Additional objectives include testing both general and functional quality-of-life outcomes and satisfaction with therapy reported by the subject.
Sponsors and collaborators
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Registry information
Official study title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Fixed Doses (50 mg, 100 mg) of Desvenlafaxine Sustained-Release Tablets in Adult Outpatients With Major Depressive Disorder
Important dates
- Study start
- 2006
- Study completion
- 2007
- First posted
- Jan 16, 2006
- Registry last updated
- Dec 28, 2007
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
CBT+ for Depression
NCT06001346
Behavior, Behavioral Symptoms
Ames, Iowa, United States
View Trial DetailsIndividualized (fMRI-guided) TMS Treatment for Depression
NCT06266390
Behavior, Behavioral Symptoms
Philadelphia, Pennsylvania, United States
View Trial DetailsA Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder
NCT06267846
Behavior, Behavioral Symptoms
Little Rock, Arkansas, United States
View Trial DetailsTesting a Transdiagnostic TMS Treatment Target
NCT06282146
Anxiety Disorders, Behavior
Boston, Massachusetts, United States
View Trial Details